November 2018 Briefing – Family Practice
Physician's Weekly,
November 2018 Briefing – Diabetes
Physician's Weekly,
Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk
Physician's Weekly,
Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
Cardiovascular (CV) Disease and Diabetes: New ACC Guidelines for use of two major new classes of diabetes drugs — sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) for reduction of adverse outcomes
Pharmaceutical Intelligence,
Cardiovascular (CV) Disease and Diabetes: New ACC Guidelines for use of two major new classes of diabetes drugs — sodium-glucose…